Disrupted Medical Conferences: What does it mean for Italian pharmas?Len Starnes
Presentation given during a Merqurio.it webinar 26 March 2021. Outlines the implications of covid-disrupted medical society conferences for the Italian pharma industry and the pharma industry in general: likely conference formats 2021; emerging formats 2022 and beyond; % Italian doctors attending major events; hybrid complexity from a pharma perspective; 4 key pharma survival strategies.
Keynote: The Future of Healthcare Events Len Starnes
Keynote presented at 'The Future of Healthcare Events Forum', Malmö, Sweden, 12 - 14 Feb 2019. Forum attendees were events professionals but insights have significant relevance for all healthcare stakeholders.
Doctors' Social Networks: Boosting standards of medical care. Supporting heal...Len Starnes
Presentation given to doctors from the MENA/GCC region outlining the scale of doctors’ social networks worldwide and their impact on the practice of medicine. Special focus on the potential of networks in the MENA/GCC region, highlighting opportunities they offer to support national healthcare reform programmes. Lessons and parallels from China.
Digital disruption: What should patient organizations do to stay ahead?Len Starnes
Extended version of a presentation given at Roche's International Experience Exchange for Patient Organizations conference, Athens, 14 - 15 March, 2018. #IEEPO2018
Virtual Conferencing: A Roadmap for PharmaLen Starnes
A pragmatic Roadmap for the pharmaceutical and medtech industries to digitize their conference and events channels. Presentation is a follow-up to an earler deck: 'The Medical Conference is Dead. Long Live the Medical Conference'.
Disrupted Medical Conferences: What does it mean for Italian pharmas?Len Starnes
Presentation given during a Merqurio.it webinar 26 March 2021. Outlines the implications of covid-disrupted medical society conferences for the Italian pharma industry and the pharma industry in general: likely conference formats 2021; emerging formats 2022 and beyond; % Italian doctors attending major events; hybrid complexity from a pharma perspective; 4 key pharma survival strategies.
Keynote: The Future of Healthcare Events Len Starnes
Keynote presented at 'The Future of Healthcare Events Forum', Malmö, Sweden, 12 - 14 Feb 2019. Forum attendees were events professionals but insights have significant relevance for all healthcare stakeholders.
Doctors' Social Networks: Boosting standards of medical care. Supporting heal...Len Starnes
Presentation given to doctors from the MENA/GCC region outlining the scale of doctors’ social networks worldwide and their impact on the practice of medicine. Special focus on the potential of networks in the MENA/GCC region, highlighting opportunities they offer to support national healthcare reform programmes. Lessons and parallels from China.
Digital disruption: What should patient organizations do to stay ahead?Len Starnes
Extended version of a presentation given at Roche's International Experience Exchange for Patient Organizations conference, Athens, 14 - 15 March, 2018. #IEEPO2018
Virtual Conferencing: A Roadmap for PharmaLen Starnes
A pragmatic Roadmap for the pharmaceutical and medtech industries to digitize their conference and events channels. Presentation is a follow-up to an earler deck: 'The Medical Conference is Dead. Long Live the Medical Conference'.
Fico unleashes new analytics for fighting america's $700+ billion healthcare ...aldrencarlo
FICO Insurance Fraud Manager 3.3 adds link analysis, facility model to boost detection of fraud rings and suspicious providers
MINNEAPOLIS, Oct. 2, 2012 -- /PRNewswire/ -- FICO (NYSE:FICO), the leading provider of predictive analytics and decision management technology, today released the latest version of FICO® Insurance Fraud Manager, the most advanced system for detecting and preventing healthcare insurance fraud, waste and abuse. FICO® Insurance Fraud Manager 3.3 integrates link analysis with business rules and predictive analytics, and also adds a facility model for detecting fraud at a hospital or an outpatient provider.
"Fraud has always been a part of the insurance business, but the magnitude of insurance fraud today is startling," said Russ Schreiber, who leads FICO's insurance practice. "Experts estimate the annual cost of health care fraud, waste and abuse in the US to be upwards of $700 billion, and last May one Medicare fraud scam alone racked up $452 million. Now, with FICO Insurance Fraud Manager 3.3, insurers have a better way to fight back."
FICO Insurance Fraud Manager 3.3 boasts the first fully integrated link analysis capability with an insurance fraud application. Insurers who previously had to configure separate link analysis tools can now save time and improve results with an easy-to-use solution preconfigured to use health care claims data. With FICO Insurance Fraud Manager 3.3, insurers can investigate organized fraud rings using the visualization capabilities of a proven link analysis tool set, and easily create displays that reveal connections between disparate claims, patients and providers.
"Integrating link analysis with Insurance Fraud Manager's powerful analytics and our advanced business rules gives insurers three ways to combat fraud, waste and abuse," said James Evans, vice president of network and financial management at McKesson Health Solutions, which provides Insurance Fraud Manager's analytics to U.S. insurers via its InvestiClaim® solution. "This triple protection gives insurers a powerful tool for fighting fraud, waste and abuse."
The new facility model in FICO® Insurance Fraud Manager 3.3 scans enormous volumes of claims data for recurring, suspicious activity at a hospital or an outpatient provider. Telltale signs may include unusual scheduling with a single patient, unusually expensive procedures, and even such issues as patients being discharged and readmitted, which can indicate problems with quality of care.
Universal American, which piloted this model with FICO, received a 2012 FICO Decision Management Award this month for its use of FICO Insurance Fraud Manager to control costs and prevent fraud losses. Universal American, a leading provider of health benefits to people with Medicare, has implemented the FICO Insurance Fraud Manager solution into their claims workflow prior to payment, and integrated it with their claims platform, Facets.
mHealth and Digital Masters : Novartis Vs KodakJoseph Pategou
During years, pharma companies have been trying to bring more value to patients and physicians by using mHealth.
In this study we observed the consequences of a slow transition to digital on a leader in his sector (Novartis Vs Kodak). We also think that pharma companies need to move from mHealth to Digital Masters to bring the best value to all stakeholders.
Some facts:
Digital Masters outperform their peers*
-26% more profitable than their average industry competitors
-9% percent more revenue with their existing physical capacity
-More efficiency in their existing products and processes
-More Productivity
(*): LEADING DIGITAL: Turning technology into business transformation, Havard Business Review press
This slide deck is comprised of lectures delivered at Nova Southeastern University Colleges of Medicine (MI) and Pharmacy (PHA) in the following courses:
MI 6410 Consumer Health Informatics and Web 2.0 in Healthcare
PHA 5203 Consumer Health Informatics and Web 2.0 in Healthcare
Medical Mobile Apps: The Regulatory StoryNadja Bester
What's life sciences' take on the booming app industry? If regulatory has anything to do with it, it'll start with a whole lot of responsible development.
The FDA Digital Health Center of Excellence and the Advancement of Digital He...Greenlight Guru
The FDA Digital Health Center of Excellence is part of the planned evolution of the digital health program with the intent to drive synergy for digital health efforts, align strategy with implementation, prepare the FDA for the digital health future, and protect patients and maintain the FDA standards of safety and effectiveness.
Ultimately, the program works to strategically advance science and evidence for digital health technologies that meets the needs of
stakeholders.
This free in-depth webinar, presented by Matthew DiamondChief Medical Officer, Digital Health Center of Excellence, will cover the digital health landscape and areas of application, goals and outcomes, planned services and launch plan, and the current areas of focus - including AI/ML-Based SaMD.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
European Directory of Health Apps 2013 (European Commission Directorate General for Communications Networks, Content and Technology).
http://www.alfonsogadea.es/apps-salud-poniendo-orden/
Pharma Digital Marketing - 5 future trendsmarcmunch2014
Digital Marketing within the Pharma Industry:
The first and safer way is to summarize the past 12 months, the second, more dangerous but also more exciting is to predict what will happen in 2015.
For years digital marketing was treated as a fifth wheel in pharma business. Whatever we say, the truth is that those organisations are made of sales force. And a digital sales force was just another marketing gimmick that does not add value but a workload and cost.
However, during past few years this traditional sales force thinking was challenged. Payers pressure forced companies to reduce ranks of sales representatives. Regulatory decisions have limited possibility of sales rep to meet HCPs. The result is that sales rep cannot meet his Client often enough to detail the product and maintain relationship in the same time.
Digital came to help with e-detailing and web-based self-detail solutions. CRM software supports reps with data that allow reps to have a meaningful conversation with HCPs they barely know.
Combining detailing visits with digital tatics and good old direct marketing is our new buzz word: Multi Channel Marketing or Multi Channel Sales
Pharma Marketing Digital Trends to Watch in 2020. A closer look at some of the future directions that Pharma Marketing need in 2020 to arm themselves for in full readiness for the next 12 Months
Healthcare in Blockchain overview by Lea Dias, CEO, Quaefacta, November 11, 2020. Key use cases include the following:
1) PHARMA & MEDICAL DEVICES SUPPLY CHAIN TRACEABILITY
2) MEDICAL RECORDS INTEROPERABILITY
3) DIGITAL IDENTITY
4) CLINICAL TRIALS VERIFICATION
5) GENOMICS DATA SEQUENCING
Market Research Reports, Inc. has announced the addition of “The Mobile Healthcare (mHealth) Bible: 2015 - 2020” research report to their offering. See more at- http://mrr.cm/ZuA
XX in Health Week 2013 SF Mixer at Practice FusionLauren Fifield
Exploring the concept of the expert, how newcomers have transformed other industries, the role of the newcomer in healthcare, and how we can actively engage talent to enter our industry.
mHealth Israel_Technology, Data & Medical Technologies- the Perfect Storm_Bos...Levi Shapiro
Presentation by Jonathan Goldstein, Director, Corporate R&D and Venture at Boston Scientific on November 5th, 2020. Covers the historical progression of transformational technological disruption and the opportunities in cardiac devices. These include heart failure products, proctoring in pacemakers as well as Clinical Data and Big Data.
Our aim is to demonstrate solidarity within
the EU on COVID-19. We propose to develop an
on-line platform „COVID-19 Smart Response“
to provide non-public actors in the EU with tools and instruments to share related know-how and resources for mitigation of COVID-19 crisis.
In the case of COVID-19, where expertise is particularly thin, non-governmental actors, companies, NGOs, academia will be particularly important partners helping to anticipate potential remedies. Multi-stakeholder approaches become increasingly necessary.
Fico unleashes new analytics for fighting america's $700+ billion healthcare ...aldrencarlo
FICO Insurance Fraud Manager 3.3 adds link analysis, facility model to boost detection of fraud rings and suspicious providers
MINNEAPOLIS, Oct. 2, 2012 -- /PRNewswire/ -- FICO (NYSE:FICO), the leading provider of predictive analytics and decision management technology, today released the latest version of FICO® Insurance Fraud Manager, the most advanced system for detecting and preventing healthcare insurance fraud, waste and abuse. FICO® Insurance Fraud Manager 3.3 integrates link analysis with business rules and predictive analytics, and also adds a facility model for detecting fraud at a hospital or an outpatient provider.
"Fraud has always been a part of the insurance business, but the magnitude of insurance fraud today is startling," said Russ Schreiber, who leads FICO's insurance practice. "Experts estimate the annual cost of health care fraud, waste and abuse in the US to be upwards of $700 billion, and last May one Medicare fraud scam alone racked up $452 million. Now, with FICO Insurance Fraud Manager 3.3, insurers have a better way to fight back."
FICO Insurance Fraud Manager 3.3 boasts the first fully integrated link analysis capability with an insurance fraud application. Insurers who previously had to configure separate link analysis tools can now save time and improve results with an easy-to-use solution preconfigured to use health care claims data. With FICO Insurance Fraud Manager 3.3, insurers can investigate organized fraud rings using the visualization capabilities of a proven link analysis tool set, and easily create displays that reveal connections between disparate claims, patients and providers.
"Integrating link analysis with Insurance Fraud Manager's powerful analytics and our advanced business rules gives insurers three ways to combat fraud, waste and abuse," said James Evans, vice president of network and financial management at McKesson Health Solutions, which provides Insurance Fraud Manager's analytics to U.S. insurers via its InvestiClaim® solution. "This triple protection gives insurers a powerful tool for fighting fraud, waste and abuse."
The new facility model in FICO® Insurance Fraud Manager 3.3 scans enormous volumes of claims data for recurring, suspicious activity at a hospital or an outpatient provider. Telltale signs may include unusual scheduling with a single patient, unusually expensive procedures, and even such issues as patients being discharged and readmitted, which can indicate problems with quality of care.
Universal American, which piloted this model with FICO, received a 2012 FICO Decision Management Award this month for its use of FICO Insurance Fraud Manager to control costs and prevent fraud losses. Universal American, a leading provider of health benefits to people with Medicare, has implemented the FICO Insurance Fraud Manager solution into their claims workflow prior to payment, and integrated it with their claims platform, Facets.
mHealth and Digital Masters : Novartis Vs KodakJoseph Pategou
During years, pharma companies have been trying to bring more value to patients and physicians by using mHealth.
In this study we observed the consequences of a slow transition to digital on a leader in his sector (Novartis Vs Kodak). We also think that pharma companies need to move from mHealth to Digital Masters to bring the best value to all stakeholders.
Some facts:
Digital Masters outperform their peers*
-26% more profitable than their average industry competitors
-9% percent more revenue with their existing physical capacity
-More efficiency in their existing products and processes
-More Productivity
(*): LEADING DIGITAL: Turning technology into business transformation, Havard Business Review press
This slide deck is comprised of lectures delivered at Nova Southeastern University Colleges of Medicine (MI) and Pharmacy (PHA) in the following courses:
MI 6410 Consumer Health Informatics and Web 2.0 in Healthcare
PHA 5203 Consumer Health Informatics and Web 2.0 in Healthcare
Medical Mobile Apps: The Regulatory StoryNadja Bester
What's life sciences' take on the booming app industry? If regulatory has anything to do with it, it'll start with a whole lot of responsible development.
The FDA Digital Health Center of Excellence and the Advancement of Digital He...Greenlight Guru
The FDA Digital Health Center of Excellence is part of the planned evolution of the digital health program with the intent to drive synergy for digital health efforts, align strategy with implementation, prepare the FDA for the digital health future, and protect patients and maintain the FDA standards of safety and effectiveness.
Ultimately, the program works to strategically advance science and evidence for digital health technologies that meets the needs of
stakeholders.
This free in-depth webinar, presented by Matthew DiamondChief Medical Officer, Digital Health Center of Excellence, will cover the digital health landscape and areas of application, goals and outcomes, planned services and launch plan, and the current areas of focus - including AI/ML-Based SaMD.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
European Directory of Health Apps 2013 (European Commission Directorate General for Communications Networks, Content and Technology).
http://www.alfonsogadea.es/apps-salud-poniendo-orden/
Pharma Digital Marketing - 5 future trendsmarcmunch2014
Digital Marketing within the Pharma Industry:
The first and safer way is to summarize the past 12 months, the second, more dangerous but also more exciting is to predict what will happen in 2015.
For years digital marketing was treated as a fifth wheel in pharma business. Whatever we say, the truth is that those organisations are made of sales force. And a digital sales force was just another marketing gimmick that does not add value but a workload and cost.
However, during past few years this traditional sales force thinking was challenged. Payers pressure forced companies to reduce ranks of sales representatives. Regulatory decisions have limited possibility of sales rep to meet HCPs. The result is that sales rep cannot meet his Client often enough to detail the product and maintain relationship in the same time.
Digital came to help with e-detailing and web-based self-detail solutions. CRM software supports reps with data that allow reps to have a meaningful conversation with HCPs they barely know.
Combining detailing visits with digital tatics and good old direct marketing is our new buzz word: Multi Channel Marketing or Multi Channel Sales
Pharma Marketing Digital Trends to Watch in 2020. A closer look at some of the future directions that Pharma Marketing need in 2020 to arm themselves for in full readiness for the next 12 Months
Healthcare in Blockchain overview by Lea Dias, CEO, Quaefacta, November 11, 2020. Key use cases include the following:
1) PHARMA & MEDICAL DEVICES SUPPLY CHAIN TRACEABILITY
2) MEDICAL RECORDS INTEROPERABILITY
3) DIGITAL IDENTITY
4) CLINICAL TRIALS VERIFICATION
5) GENOMICS DATA SEQUENCING
Market Research Reports, Inc. has announced the addition of “The Mobile Healthcare (mHealth) Bible: 2015 - 2020” research report to their offering. See more at- http://mrr.cm/ZuA
XX in Health Week 2013 SF Mixer at Practice FusionLauren Fifield
Exploring the concept of the expert, how newcomers have transformed other industries, the role of the newcomer in healthcare, and how we can actively engage talent to enter our industry.
mHealth Israel_Technology, Data & Medical Technologies- the Perfect Storm_Bos...Levi Shapiro
Presentation by Jonathan Goldstein, Director, Corporate R&D and Venture at Boston Scientific on November 5th, 2020. Covers the historical progression of transformational technological disruption and the opportunities in cardiac devices. These include heart failure products, proctoring in pacemakers as well as Clinical Data and Big Data.
Our aim is to demonstrate solidarity within
the EU on COVID-19. We propose to develop an
on-line platform „COVID-19 Smart Response“
to provide non-public actors in the EU with tools and instruments to share related know-how and resources for mitigation of COVID-19 crisis.
In the case of COVID-19, where expertise is particularly thin, non-governmental actors, companies, NGOs, academia will be particularly important partners helping to anticipate potential remedies. Multi-stakeholder approaches become increasingly necessary.
GLOBAL VACCINATION: HOW THE EVOLVING HEALTHCARE INFRASTRUCTURE IS SUPPORTING ...Anayasharma10
COVID-19 (coronavirus) vaccines have started becoming accessible in most countries and are probably a severe product in fighting the pandemic in 2021. Several vaccines are already in the development trails or phase three trials that have reported promising data in the initial phase, with some receiving authorization for use.
COVID-19 BEST PPT EVER MADE (FULLY DETAILED)SHAURYAANCHAL
HELLO FRIENDS THIS IS THE BEST PPT MADE ON COVID 19 AND VERY INFORMATIVE CONTENT EVER MADE.
YOU CAN USE THIS IN YOUR SCHOOL PROJECT OR IN OTHER ARTICLES, YOU ALSO DON'T NEED TO SEARCH OVER EACH TOPIC IN INTERNET.
THE WHOLE PPT(POWERPOINT PRESENTATION) IS ENOUGH FOR YOU.
ALL THE BEST FOR YOUR PROJECT/WORK
REGARDS/MADE BY
SHAURYA ANCHAL
EMAIL ID : shauryaanchalofficial@gmail.com
Our ebook 'Communicating in a Crisis' explores how public relations was successfully used in the pandemic and features case studies from agency, in-house and public sector teams shortlisted in our 2021 Excellence Awards.
The role of healthcare professionals is to: intervene/prevent migration of diseases. Injury and other health conditions around the world.
Done Through:
Surveillance of cases. Promotion of healthy behaviors in communities and environments.
La INFODEMIA es un neologismo que expresa la sobreinformación que sobre un tema se genera, en algunos casos de forma precisa y en otros no, y que hace difícil a las personas encontrar fuentes fiables para encontrar orientación cuando se necesita. Este gran volumen de información de un tema específico en un corto periodo de tiempo origina una “infoxicación”, es decir, una intoxicación por información. Si esta intoxicación se asocia a una pandemia actual (como la COVID-19) el término infodemia guarda un razonable parecido, teniendo en cuenta que en el “totum revolutum” es campo sembrado para los dimes y diretes, para la rumorología, la información errónea y la manipulación de las noticias con intenciones dudosas. En la era de las nuevas tecnologías de la información y comunicación, de la Web 2.0, 3.0, 4.0… y las que vengan, este fenómeno se amplifica a través de las redes sociales, ese patio de vecinos sin control, extendiéndose más y más rápido que un virus esta información inválida o tóxica: de ahí el término “viralización”.
Si juntamos los efectos del virus SARS-CoV-2 con los efectos de la viralización de las redes sociales, y teniendo en cuenta dos principios conocidos en la comunicación periodística (que una buena noticia no es noticia y que las falacias se difunden más rápido que las verdades), tenemos el cóctel perfecto para crear el caos, el miedo y la COVIDofobia.
Y para que conste la preocupación por la infodemia basta revisar el documento adjunto de la PAHO (Pan American Health Organization), miembro de la Wordl Health Organization, donde se exponen algunos datos de interés para conocer la dimensión de este problema: en el último mes se han volcado 361 millones de vídeos en YouTube en relación con el tema de la COVID-19 y cerca de 20.000 artículos sobre el tema en Google Scholar, así como 550 millones de tweets en un mes que incluían el término COVID-19 o pandemia.
Es crítico disponer del acceso a la información, pero en el momento adecuado y en el formato adecuado. Hoy todo gira sobre lo mismo. Desayunamos, comemos, merendamos, cenamos y hasta dormimos con la misma noticia, visto desde tantas perspectivas y con tantos autoproclamados expertos que ya nos sabemos a qué atenernos. En este ambiente de infodemia, donde campa a sus anchas la prensa amarillista y los que sientan cátedra con la osadía de su desconocimiento, no se pueden aplicar los principios de calma y coherencia tan necesarios para la toma de decisiones.
Why Data-Driven Healthcare Is the Best Defense Against COVID-19Health Catalyst
COVID-19 has given data-driven healthcare the opportunity to prove its value on the national and global stages. Health systems, researchers, and policymakers have leveraged data to drive critical decisions from short-term emergency response to long-term recovery planning.
Five areas of pandemic response and recovery stand out for their robust use of data and measurable impact on the course of the outbreak and the individuals and frontline providers at its center:
Scaling the hospital command center to pandemic proportions.
Meeting patient surge demands on hospital capacity.
Controlling disease spread.
Fueling global research.
Responding to financial strain.
Our central thesis has long been that COVID hasn’t dramatically changed the healthcare industry, rather it has dramatically accelerated different trends in the healthcare space that were already simmering before March 2020. Given the usually slow pace at which the healthcare market typically moves, COVID served as a shock to the system and an accelerator that created a window to drive meaningful change. In this whitepaper, we will examine several changes that were less obvious in the early days of the pandemic and assess their longevity as we (hopefully) move into a post-COVID world.
This report has been developed by Medicus AI, a leading technology company supporting the diagnostic testing partners with an innovative digital health solution.
We embarked on this study to better assess and understand the challenges facing medical biologists and the healthcare industry, and to identify solutions to support a new era of healthcare.
The research included over 2,200 survey participants, and almost 20 expert interviews, and was completed in December 2020.
Here’s How All Of Us Can Use Technology To Help Tackle CoronavirusBernard Marr
Technology is used in different ways to help the world tackle coronavirus (COVID-19). In this article, we look at how everyone one of us can help in the fight using technology and crowdsourcing.
Health Catalyst Launches COVID-19 Patient Data Repository to Speed Vaccine De...Health Catalyst
With a lack of historical population-based information to steer COVID-19 research, pharmaceutical companies are struggling to understand the everchanging virus as they work tirelessly to develop a vaccine in less than one year. Research teams can access near real-time COVID-19 patient data with Touchstone® for COVID-19 National Data Sets and Registry from over 80 million patients across the United States and three national data sources: John Hopkins University, The New York Times, and The COVID Tracking Project.
The Registry offers up-to-date, comprehensive data with outcome analysis and clinical trial analysis so research teams can stay up to date through every stage of the vaccine development process.
Future of Healthcare Provision Jan 2017Future Agenda
Building on insights from our 2015 future of health discussions, this is a new initial view on how healthcare provision may change, especially given emerging opportunities for improved patient engagement. As well as insights from discussions in India, UK, Canada, Singapore and the US it also includes other additional perspectives shared in interviews and workshops over the past 12 months.
We recognise that given the multi-factored nature of this topic and the rapid emergence of new options, what we have summarised in this document is itself in flux. As such, over the next few months we will be sharing this more widely for additional feedback ahead of publication of an updated paper over the summer. So, if you have any comments on changes and additions or issues that you think need more detail, please let us know and we will include.
As with all Future Agenda output, this is being published under creative commons (share alike non commercial) so you are free to share and quote as suits.
Are you wondering how the digital health scene is responding to the Corona crisis and how innovations can have an impact beyond COVID-19?
What kind of digital health innovations are coming up at the moment and could they be a real game changer? And what about the time after COVID-19? Can we hope for a more connected healthcare in the future?
Our expert Elisa Frenz, Chief Digital Officer at Health Proc Europe, is going to provide you with the answers in an interactive dialogue. In order to connect the dots and accelerate impact, your ideas and opinions on the topic are wanted!
Similar to CORONAVIRUS: How Doctors' Social Networks Fight the Pandemic (20)
The new normal is already here. A 'new' new normal loomsLen Starnes
This presentation is an update to a 2-part review of disrupted medical conferences published on Pharmaphorum March 15th and 16th 2022 .
It reflects recent trends and current disruptive global warnings, events, and threats likely to further impact medical meetings
Disrupted medical conferences: THE BIG PICTURELen Starnes
An in-depth analysis of the impact of covid on medical conferences: lessons learnt 2020-2021; consequences for all major stakeholders 2022; scenarios for 2022 and beyond. A visual abstract presents the full analysis.
The future of scientific congresses: what can we learn from the medical world?Len Starnes
Keynote presentation given during the November 26 Digital University Day organized by the Delft University of Technology, The Netherlands. Focuses on the transformation of medical society congresses to virtual formats during 2020, highlighting outcomes relevant for academic science and technology events.
شبكات تواصل اجتماعي للأطبّاءتعزيز معايير الرعاية الطبّيّة دعم برامج الرعاية...Len Starnes
عرض تقديمي يقدّم للأطبّاء من منطقة الشرق الأوسط وشمال إفريقيا ودول مجلس التعاون الخليجي يوضّح مكانة شبكات الأطبّاء الاجتماعيّة في العالم وتأثيرها على ممارسة مهنة الطبّ. تركيز خاصّ على إمكانيّات الشبكات الكامنة في منطقة الشرق الأوسط وشمال إفريقيا ودول مجلس التعاون الخليجي، مع التركيز على الفرص التي تقدّمها لدعم برامج الإصلاحات الوطنيّة في مجال الرعاية الطبيّة. دروس ومقارنات من الصين.
Will global HCPs networks become communities of choice for rare-disease speci...Len Starnes
Analysis of the role of global HCPs' social networks in the management of rare diseases. Case study of the G-Med global neuroendocrine tumour specialist community
Physicians' Social Networks: A New Tool in Global Health Len Starnes
Presentation first given at the Digital Health Summit Turkey, Istanbul, December 17 2015. Focus of the presentation is the emerging role of physicians' social networks in supporting national health reform programmes and managing pandemic threats.
Emergent hybrid medical society conferences: evidence of disruption; impact o...Len Starnes
Presentation first given at the 2015 Eyeforpharma Barcelona Conference; an update of a presentation given in 2013 on the emergent hybrid medical society physical/virtual conference format. Evidence of conference format disruption is presented based on the 2014 European Society of Cardiology Congress. The impact on the pharma industry is explored.
Going social: why patient organizations cannot ignore social media Len Starnes
Presentation goven at the 7th Annual International Experience Exchange for Patient Organizations, Munich, 3 - 4 March 2015; #IEEPO2015. The event was sponsored by Roche.
Some 300 participants attended representing over 40 patient organizations worldwide. The final day of the meeting was dedicated to social media and how they can help patient organizations achieve their goals
The Rise and Rise of HCPs' Social Networks - Focus on GCC RegionLen Starnes
Presentation given at the 5th Saudi eHealth Conference, Riyadh, 18 – 20 November 2014. The agenda includes: an update on the status of the continuing global expansion of HCPs’ social networks; a look at networks in the Gulf Cooperation Council (GCC) region; an overview of differentiating network characteristics; physicians’ usage patterns; impacts on national healthcare systems; and a case for the creation of a dedicated Saudi Arabian network to support the objectives of the country’s new healthcare reform.
This presentation served as the basis of a Twitter reporter training programme developed for the 2014 European Society of Cardiology Congress which took place in Barcelona August 30th to September 3rd.
It asks the question: what is a ‘valuable tweet’ in the context of a medical society conference? It further explores the ontology of tweets that could be regarded as valuable during medical meetings and conferences.
Whilst the issue of the use of Twitter at medical conferences has been intensively discussed during recent years, the focus of the dialogue has primarily been the nature and scale of the disruption on traditional physical conference formats. By contrast, this presentation explores the qualitative nature of tweets that add value to scientific debate.
Comments on this presentation would be most welcome.
Presentation delivered at the Russian Pharmaceutical Forum, St Petersburg, 17 - 19 June 2014, an update of a presentation first delivered in 2012: 'Making sense of multichannel'. The focus is on the progress of pharma multichannel marketing during the period 2012 to 2014, highlighting frequently cited hurdles, significant common practices, and emerging trends.
#ChatAfib: Pharma industry's first-ever open tweet chatLen Starnes
Analysis of the pharma industry's first.ever tweet chat: Boehringer Ingelheim's #ChatAfib, staged during the 2013 European Society of Cardiolgy Congress. The first of two presentations exploring the impact of social media and digital technologies on professional medical conferences
Introductory presentation to an EphMRA Masterclass workshop follow-up webinar given 6 December 2012. The original Masterclass workshop was delivered in Paris June 2012 at the EphMRA '360 Future' conference.
This translation was made possible with the kind and generous help of Jahee Lee, Dreamwiz, Korea. www.dreamwiz.com
In Korean: Making Sense of Multichannel (in the pharma industry)Len Starnes
Presentation first given at the Digital Health Summit Turkey, Istanbul, 11 – 12 September 2012. This was the first event of its type in Turkey with representatives of all major healthcare stakeholders: HCPs, patients, pharma, payers, government, academia, regulators, digital agencies and the media. Some 200 delegates participated.
http://www.ptms.com.tr/
This translation was made possible by the kind and generous help of Jahee Lee, Dreamwiz, Korea. www.dreamwiz.com
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
2. The covid-19 pandemic requires
unprecedented levels of collaboration
and knowledge sharing globally.
Doctors’ social networks are in a
unique position to do just this
This review of initiatives, started by
doctors’ social networks to help fight
the pandemic, is designed to inform
and inspire other networks which are
perhaps considering how they too can
best help.
Content will be updated regularly as
new initiatives emerge and as other
networks contribute.
3. Content in this review is based on
direct email responses from
networks, telephone and Skype
interviews, press releases, and
blog posts.
Content was collated during the
period 16 - 23 March 2020.
6. Responses from DXY specifically address 5 questions
DXY: Most of your questions are related to data. Before answering these, I want to
highlight that data is one of three focus areas for DXY: data, content, consultation.
Q1. Has DXY been officially asked to help collate data by the Chinese government?
DXY: No. DXY was not officially asked to help to collate data. DXY choose to do this
voluntarily.
On January 21, DXY launched the map to track the virus. Coincidentally, the day before,
Dr Zhong Nanshan announced the first confirmed human-human transmission.
The DXY founders and executive team have extensive professional training and experience
in medicine and public health, so the team’s instinct was that a disease map would be the
optimal way to track the outbreak and trends of the disease. Even without information
about other aspects of the disease, we knew that making this information accessible
would be important.
7. Q2. How is the data collected?
The data is collected both automatically and manually from many sources, including
local governments. The data is in inconsistent formats, some text, word, pdf and
even image files. There is no common data format or single central source to use to
collate the data.
It is important to DXY to provide accurate data, so we made careful efforts to collect
and clean the data especially while monitoring changes accurately. Different local
governments released updated data at different times in the day so coordinating
within DXY was critical. In some cases, we sacrificed speed of release of updated
data for accuracy of that data.
8. Q3. How is the data shared with the Johns Hopkins covid-19
interactive map* (manually, automated)?
The data was shared with Johns Hopkins University in both
ways. JHU crawled the DXY data. JHU came to DXY directly to
clarify timing of updates and any changes to the data.
*https://www.arcgis.com/apps/opsdashboard/index.html#/bda75947
40fd40299423467b48e9ecf6
9. Q4. Are DXY members able to provide insights/recommendations that government
resources are not?
Absolutely. For example, we noticed that in the Hubei province statistics, the city of
XiangYang was not included. After observing this discrepancy, we contacted the
provincial government and they included the XiangYang data going forward.
In addition, as the crisis developed, the city of Wuhan received most of the attention
from concerned citizens and organizations in China and around the world. We
leveraged the DXY platform to highlight that Huangshi, XiangYang, TianMen, and other
cities lacked the medical resources they needed while their case numbers grew. DXY
published requests for face masks and other medical resources and the response was
overwhelming – directly to the local hospitals who needed it.
DXY wanted to help the hospitals to save patient lives and direct resources to the right
places.
10. Q5. How does DXY see its role in taming the coronavirus pandemic during
the next 3 months?
Work still needs to be done in China.
The mission of DXY is to connect trusted professionals with each other, with patients
and with society to support more health and a better life. DXY does this by providing
data, content, and online consultation.
Over the next three months, I am optimistic the pandemic might disappear and patients
will recover. We see things moving in a positive direction. In China, DXY will focus on
educating the public about healthy lifestyles and delivering science-based messages
about the disease, prevention and treatment.
The public is eager to understand the disease and what they can do to protect
themselves. DXY will accelerate its efforts to be a leader in healthy lifestyles and
protection against COVID-19 across all of its channels, including baby care, sleep care,
skin care, mental health and others. (continued)
11. DXY will continue working with the healthcare ecosystem, including WHO China and the
Bill & Melinda Gates Foundation, to promote healthy lifestyles and relieve the concerns
of the public about disease management.
DXY also will work with other private sector companies committed to supporting
healthy lifestyles and products that help the public to do so.
Lastly, as the COVID-19 pandemic subsides, DXY plans to maintain a team to track
trends in infectious diseases including COVID-19, MERS, SARS, Zika, dengue and others.
The impact of climate change means that mosquito-borne diseases like dengue and
malaria will spread beyond regions where they have been common in the past.
Stanley Li
Chairman, DXY
13. Responses from Coliquio specifically address 3 questions
Q1. Do you host a dedicated coronavirus forum?
Yes, we have a dedicated forum where we gather all relevant insights.
Besides up-to-date articles about diagnosis and treatment, practice
management and billing, we are offering a wide range of information and
support to our doctors, for example:
- Downloadable patient information for medical practices: STOP sign for
the practice front door; inform patients suspected of being infected with
the covid-19 pathogen before they enter the practice; notice with patient
information for waiting rooms; important rules of conduct for patients.
- Interviews/Testimonials: how other doctors deal with covid-19 in practice.
(continued)
14. - Short video tutorials such as ‘Make your own hand sanitizer in 4
steps’ https://www.youtube.com/watch?v=RVmMKI7gTdc
- A hotline (via mail) for the most urgent questions from our members. The
most relevant and frequently asked questions are published on our
platform, including the answers, of course.
Naturally we closely follow all questions and comments on the forum in
order to react directly to the needs of the doctors, and to find quick and
competent solutions to their informational needs.
15. Q2. Do you provide data or recommendations to national
healthcare/public health authorities?
- We built a separate, open landing page
https://www.coliquio.de/arzt/praxis/coronavirus/covid-19-informationen-
fuer-aerzte/
with the most relevant information for ALL doctors/HCPs in Germany. The
25 most relevant medical societies in Germany have been informed about
this and we invited them to share this information with their members.
(continued)
16. - We published an ‘open letter’ to the German Federal Minister of
Health, Jens Spahn and his crisis management team, with the most
urgent demands of Coliquio doctors:
- Central coordination and information by authorities.
- Specification of the exact procedure for the procurement of
protective equipment.
- Assistance with labour law issues.
- Reliable information on the virus and the disease.
- Binding regulations for the compensation of financial losses.
(LS: Coliquio attached a PDF of the letter in their response. It was
headed ‘Open letter on covid-19: doctors feel insufficiently supported’)
17. Coliquio participated in the largest hackathon
that ever took place in Germany (or even
worldwide?), organized by the German
government and 7 tech start-ups. It drew more
than 43,000 participants, resulting in over
2,000 ideas – all submitted within 48 hours.
(continued)https://wirvsvirushackathon.org/
18.
19. Q3. How do you see the role of your network during the next 6 months?
The development of the last few weeks has proven our role as a reliable and
capable partner for doctors. Not only because of the exponential increase in
traffic, but also because of the volume of positive feedback, and the
appreciation of our rapid content updates. We expect to become even more
relevant as our entire team work tirelessly to provide even better and faster
services.
And we offer even more: With medflex, the latest start-up company founded
by our CEO, Felix Rademacher, we offer a messaging tool (= telemedicine
app) for doctors and patients that is particularly valuable in the current
situation. More and more doctors are now open for this (telemedicine) and
we are working 24/7 to find solutions that are especially helpful in this
pandemic crisis. For example, a patient questionnaire enabling faster
identification of suspected cases of coronavirus.
Pia Kuss,
Senior Marketing Manager, Coliquio
21. Responses from Doctors.net.uk specifically address 3 questions
Q1. Do you host a dedicated coronavirus forum?
There is currently quite a lot of activity going on regarding COVID-19.
- NEWS: top medical news stories daily are about COVID-19.
- NEWS: we have been writing weekly news features, each on a separate
aspect of COVID-19 (these have been doing really well).
- LIBRARY: Our microbiology nuts and bolts bloggers have been
contributing blog posts. (continued)
22. - FORUM: is 90% COVID-19 content
- We launched a dedicated COVID-19 forum last Tuesday (March 10).
In less than a week, more than 350 threads have been posted, and it's
becoming a major hub for doctors seeking support, clarifying confusion,
and just having a good old rant as the crisis progresses.
We have been running COVID-19 related polls in the FORUM (promoted
in the bulletin) and on the platform landing page where appropriate.
23. We have no systematic setup to deliver data/
recommendations to national bodies other
than ad-hoc features in the press.
Q2. Do you provide data or recommendations to national
healthcare/public health authorities?
24. Q3. How do you see the role of your network during
the next 6 months?
I think that it’s become clear that we will have a vital role to
play for both clients and doctors as the situation unfolds.
For both clients and doctors, our ability to bring material from
conferences that have gone from face-to-face to virtual, and
data that was due to be presented at a conference since
cancelled, to a wide and engaged community of doctors in the
UK will be highly valuable. (continued)
25. For doctors, our ability to connect doctors in the UK via the forum and
our other services at a time of ongoing crisis is arguably unmatched in
the UK, and we have already seen the great support they are receiving
from one another over the past few weeks.
We are augmenting this with our medical news services, news
features, blog content and other clinical resources. We are planning to
extend our resources to include tailored advice on legal issues,
financial changes and considerations, mental health support and other
practical aspects relating to the COVID-19 crisis, so we become a truly
holistic hub for our members at this uncertain time.
Ria Carruthers
Head of Community, Doctors.net.uk
28. https://blog.doximity.com/articles/covid-19-e-re-here-to-help
A sincere, heartfelt THANK YOU to those on the COVID-19 front
lines. Below are some of our extra efforts to help you in this time of
crisis.
Free Dialer access expanded to all U.S. healthcare staff
Dialer in the Doximity app, historically available only to physicians,
NPs (Nurse Practitioners) and PAs (Physician Assistants), has been
scaled up to support everyone in your entire workforce through
2020. Physician-led care teams can now call patients from their cell
phone while displaying the office/hospital number on the patient’s
Caller ID. Your remote and on-the-go productivity is important for
patients, which means it’s important to us. Healthcare professionals
can request access to Dialer at: https://doximity.com/care_team. If
you're looking for Step by Step instructions, please go here.
29. https://blog.doximity.com/articles/covid-19-e-re-here-to-help
Physician-curated COVID-19 news and peer commentary
Our editorial team has curated a private COVID-19
newsroom for clinicians to access timely, aggregated
updates and recommendations from across the medical
profession, while privately sharing and discussing new
research, treatment, and best practices. We’ll also continue
to publish and disseminate member perspectives sharing
direct experience and ideas from the front lines.
30. https://blog.doximity.com/articles/covid-19-e-re-here-to-help
Free COVID-19 job posts to address surge capacity
To help your facilities manage medical staffing surge needs, we’re
offering free job posts for COVID-19 related staffing. Just fill out
the form here. We’ll then tap our network to distribute your
openings to appropriate clinicians based on location, specialty,
and any other requirements. We’ll direct applicants immediately
to the contact info you provide. You can see the list of open
COVID-19 positions here, updated as soon as we get them.
We’ll keep doing everything we can to help you. These ideas came
from our physician members. What else can we do? Any and all
ideas welcome. Let us know: What can we do to help?
From our families to yours, be well and stay safe.
33. Responses from Esanum specifically address 3 questions
Q1. Do you host a dedicated coronavirus forum? If so, what are you
observing?
We do, yes. Posts split into:
- Medical information
- Calls for volunteers / organizational matters
- Ask-the-expert sessions for fact checking the numerous fake-news reports
that patients and doctors are being confronted with (such as the impact of
Ibuprofen). This is similar to the ‘Piyao yu fanghu’ (辟谣与防护), or in
English ‘rumour protection service’, that DXY is providing on its network.
(continued)
34. We have noticed that pretty much all other non-corona related information
is not in demand right now.
Many of our (pharma) clients are increasing spending on online media such
as Esanum, but are unable to adapt their content quickly enough. They
have produced their media plans way in advance and are pushing out
information that is not hitting a nerve with the audience at all, and
therefore produces inadequate results. We are advising our clients against
continuing with this strategy and have in some cases even declined to make
valuable space available in our newsletters for these types of messages.
Such ‘news’ will not make it onto the Esanum network at this time because
nobody cares.
(continued)
35. The good thing is, most of our clients are happy to adapt and are taking our
advice. They are producing, or are allowing us to produce, better and more
relevant content, or are even pausing their general product information feeds.
Instead, they are opting to post messages such as those from Gillead HIV/HCV,
which focus on the fact that their production chain and supply is secured, and
that it is safe to prescribe their drugs even in these difficult times. THESE are
the kind of messages that HCPs are additionally interested in.
We are working very closely with our staff in Italy, Germany and France.
Esanum Italy was the first to set up a dedicated covid-19 area:
https://www.esanum.it/?tags=COVID-19
(continued)
36. In general, we are not reporting news like everyone else, but are reporting
on stories behind the news.
Like this article: https://www.esanum.com/today/posts/italy-you-cant-help-
everyone-you-have-to-choose
(continued)
37. Or Podcasts and interviews with virologists / immunologists:
https://www.esanum.de/covid-19/feeds/podcasts/posts
Or articles about the impact of home working 5 days a week:
https://www.esanum.de/today/posts/wir-ruecken-virtuell-zusammen-
gemeinsam-durch-die-corona-krise
Podcast:
Interview with professor Klaus Cichutek,
president, Paul Ehrlich Institute,
German Federal Institute for Vaccines
and Biomedicines, on the development
covid-19 vaccines
(continued)
38. (continued)
Q2. Do you provide data or recommendations to national healthcare/public
health authorities? If so, what and how?
We have introduced a dashboard comparing the states of Germany to each
other. A lot of decisions on policies in Germany are made on a regional, city
and state level, not on a national level (such as how and when to lock down a
city, what kind of businesses should close, and how to support hospitals). The
states within Germany are performing very differently.
The same happens on a country level in Europe, so I believe it makes sense to
compare the performance and show it in easy-to-grasp charts.
39. (continued)
Example:
While the map on the
the lower left just shows
the German states with
their absolute number of
covid-19 infections, we
additionally provide the
numbers per 100k
inhabitants, map lower
right, and per
1000 square metres.
These maps show the
real hot spots.
40. Example:
This chart shows the infection ‘race’
between the German states. I have not
seen this kind of chart anywhere else in
the German media and I think we are
providing a valuable service here.
41. Q3. How do you see the role of your network during the next 6 months?
Networks like Esanum are right now practically the only fast and reliable
form of communication. Medical sales reps are grounded, and meetings
and congresses are cancelled.
I see the role of HCPs’ social networks becoming ever more important as
a way to communicate, enabling not only HCPs to communicate with one
another, but additionally, enabling HCPs to communicate with national
health authorities and industry.
Tom Renneberg
CEO, Esanum
43. (continued)
Statement from the CEO, G-MED
“The coronavirus pandemic demands
‘organic’ grass-roots level collaboration
and knowledge sharing within the global
medical community.
True global doctors’ social networks that
enable organic crowdsourcing are
designed to do just this.”
44. Responses from G-MED specifically address 3 questions
Q1. Do you host a dedicated coronavirus forum? If so, what are you
observing?
Yes, and it’s booming right now.
G-Med is currently running a very large global group focused on COVID-19, with
active participation of thousands of physicians from all over the world.
Physicians talk about their Real-World Experience with COVID-19 treatment,
prevention, their procedures, and insights. They are bringing up relevant
questions, clarifying issues, and sharing experiences.
(continued)
45. Topics currently being discussed include:
• Coronavirus: how is the outbreak affecting your practice?
• Approaches to coronavirus infection
• COVID-19 after recovery
• Antivirus pastille
• Hemodialysis centers
• Tests for private offices
• Nasal washing
• Germany and COVID-19
• Acyclovir and COVID-19
• COVID-19 in Brazil
• COVID-19 with zika or dengue
As always, all content in G-Med is: Global, Organic, Robust.
(continued)
46. G-MED COVID-19 discussion forum
Topic:
Treatment guidelines
Question:
Posted by US doctor
After 3 days:
18 comments
15,379 views
Germany
France
Romania
47. Q2. Do you provide data or recommendations to national
healthcare/public health authorities?
We work with data companies on COVID-19. We will be happy to
collaborate with national healthcare/public health authorities if they ask
us.
48. Q3. How do you see the role of your network during the next 6 months?
For physicians: being the largest global, organic, crowdsourcing platform for
physicians’ Real-World practice experience with COVID 19.
For the industry: being the central information and insight hub, in
additional to providing innovative tactics to engage with physicians.
Ilan Ben Ezri
CEO, G-MED
59. The Rounds
Canada’s largest network
Over 20k members
+
Over 13k Canadian pharmacists &
over 15K US pharmacists on QID.io, a
pharmacist-only social network
Canada
60. The Rounds (therounds.com) is the fastest growing physician network
in Canada and has implemented 3 important measures to support its
members, medical associations and industry partners to ensure the
flow of information is maintained and the healthcare system is
properly supported.
1. Launched a COVID-19 Community to host Expert Updates, Current
Resources and Peer Discussions. We’ve removed the borders for this
community as we are working on several partnerships with key US
health systems, hospitals and medical associations. We’ve also opened
this to other key HCPs such as nurses and pharmacists that are critical
during this pandemic. We’re establishing a medical advisory group to
ensure that the community is provided relevant information in a timely
manner.
61. 2. Cancellations of physical medical conferences has impacted
every medical association for the next few months. These
events are critical for the dissemination of medical advances,
changes to guidelines, research and sharing of best practices.
We’re connecting with these medical associations to host a
virtual conference at no charge to ensure that the members or
registered participants can access the information virtually
instead of waiting for another year to go by.
62. 3. The pharmaceutical and medical device industries are key
stakeholders in the advancements and updates that their products
provide, and with their employees being restricted to work from home
until at least the end of April, we are working on solutions so physicians
in need of information will have access to that information in a timely
manner. This is in the form of live communications, virtual exhibit halls
for branded content and continuing sponsored medical education
events for therapeutic discussions.
63. We’re replicating measure #1 from The Rounds to our pharmacy network QID
(QID.io) to support over 3,000 pharmacists that are part of The Canadian
Society of Hospital Pharmacists so that they can communicate in real-time on
developments happening at their sites and stay ahead of the curve. One of our
key US partners, The California Society of Health-System Pharmacists, is
launching a community to support the California state of emergency for their
4,000 members but also to connect with thousands of community pharmacists
from Walmart, CVS and other key pharmacies to ensure that they work together
to flatten the curve.
Tim Rice
CEO, Boondoc Technologies
64. A sincere thanks to the following for their
generous help and enthusiastic support
in developing this review
• Ria Carruthers, Head of Community, M3 (EU), UK
• Ilan Ben Ezri, CEO, G-MED, Israel
• Mark Garlinghouse, DXY, UK
• Pia Kuss, Senior Marketing Manager, Coliquio, Germany
• Stanley Li, Chairman DXY, China
• Tom Renneberg, CEO, Esanum, Germany
• Tim Rice, CEO, Boondoc Technologies Inc, Canada
• Kate White, Business Insights Director,
Communications, M3 (EU), UK
• Natalie Wolfram, Public Relations Manager, Doximity, USA
65. lenstarnes@gmail.com
T: + 49 30 781 5513
M: + 49 172 1788253
Skype: lenstarnes
www.linkedin.com/in/lenstarnes
www.twitter.com/lenstarnes
www.slideshare.net/lenstarnes
Len Starnes
Len Starnes Digital Healthcare
Research and Consulting